Biodesix, Inc. (BDSX)
Company Description
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States.
The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test.
In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection.
Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics.
The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
| Country | United States |
| IPO Date | Oct 28, 2020 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 218 |
| CEO | Mr. Scott Hutton |
Contact Details
Address:
2970 Wilderness Place, Suite 100 Boulder, Colorado 80301 United States | |
| Phone | 303-417-0500 |
| Website | biodesix.com |
Stock Details
| Ticker Symbol | BDSX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001439725 |
| CUSIP Number | 09075X108 |
| ISIN Number | US09075X1081 |
| Employer ID | 20-3986492 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Scott Hutton | President, Chief Executive Officer and Director |
| Robin Harper Cowie | Chief Financial Officer, Secretary and Treasurer |
| Ryan H. Siurek | Chief Accounting Officer |
| Dr. Heinrich Röder | Founder and Chief Technology Officer |
| Dr. Robert W. Georgantas III, Ph.D. | Chief Scientific Officer |
| Jeffrey A. Bojar | Vice President of Legal and Regulatory Affairs |
| Matt Stauffer | Vice President of Sales |
| Dr. Paul J. Beresford | Chief Business Officer |
| Dr. Gary Anthony Pestano Ph.D. | Chief Development Officer |
| Bobbi Coffin | Chief Growth Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| Dec 16, 2022 | 8-K | Current Report |
| Dec 1, 2022 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 30, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 23, 2022 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 23, 2022 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 23, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 21, 2022 | 8-K | Current Report |
| Nov 18, 2022 | 424B5 | Filing |
| Nov 16, 2022 | 424B5 | Filing |